peginterferon alfa

DRUG6 trials

Sponsors

Xiamen Amoytop Biotech Co., Ltd., Third Affiliated Hospital, Sun Yat-Sen University

Conditions

Chronic Hepatitis BHealthy Subjects

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects

CompletedNCT01343186

Xiamen Amoytop Biotech Co., Ltd.Healthy Subjects

Start: 2011-01-31End: 2011-11-30Updated: 2012-01-31

Phase 4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis B

Start: 2016-04-30End: 2019-04-30Target: 200Updated: 2019-01-15

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis B

Start: 2016-06-30End: 2019-12-31Target: 200Updated: 2019-01-15

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis B

Start: 2016-08-31End: 2019-08-31Target: 200Updated: 2018-05-22

HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis B

Start: 2016-08-31End: 2019-09-30Target: 200Updated: 2018-05-22

The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis B

Start: 2019-01-01End: 2020-12-31Target: 200Updated: 2019-01-15